^
    Back
    Association details:
    Biomarker:KRAS G12
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A single-arm phase II exploratory study of glutamine combined with oxaliplatin, capecitabine (XELOX) and bevacizumab as the first-line treatment for advanced colorectal cancer with KRAS G12D gene mutation

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500108082
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2020
    Title:

    P-225 KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

    Published date:
    07/01/2020
    Excerpt:
    This small retrospective study shows a positive trend in progression-free survival of first-line bevacizumab-based chemotherapy patients with KRAS mutation in codon 13 versus codon 12.
    Secondary therapy:
    5-fluorouracil + irinotecan; 5-fluorouracil + oxaliplatin
    DOI:
    10.1016/j.annonc.2020.04.307